Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein

Details

Serval ID
serval:BIB_6ECB8CA67EB4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein
Journal
Journal of Experimental Medicine
Author(s)
Sy  M. S., Guo  Y. J., Stamenkovic  I.
ISSN
0022-1007 (Print)
Publication state
Published
Issued date
1992
Volume
176
Number
2
Pages
623-627
Notes
PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S
Abstract
CD44H is the principal cell surface receptor for hyaluronate, which is a major glycosaminoglycan of the extracellular matrix. Expression of CD44H is enhanced in a variety of malignant tumors and correlates with tumor aggressiveness, supporting the notion that interaction between CD44H and hyaluronate may play an important role in tumor growth and dissemination. In this report we show that in vivo tumor formation by human lymphoma Namalwa cells, stably transfected with CD44H, can be suppressed by a soluble human CD44H-immunoglobulin fusion protein. Disruption of the interaction between CD44H and its physiologic ligands may provide a novel strategy for controlling tumor growth in vivo
Keywords
Animals/Antigens,CD8/immunology/Cell Division/Half-Life/Humans/Immunoglobulins/administration & dosage/genetics/Lymphoma/therapy/Mice/Mice,Nude/Neoplasm Transplantation/Receptors,Lymphocyte Homing/Recombinant Fusion Proteins/pharmacology/Solubility/Transfection/Tumor Cells,Cultured/Research
Pubmed
Web of science
Open Access
Yes
Create date
29/01/2008 18:33
Last modification date
20/08/2019 14:27
Usage data